Compare MAMA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | AVIR |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 429.1M |
| IPO Year | 2011 | 2020 |
| Metric | MAMA | AVIR |
|---|---|---|
| Price | $13.71 | $5.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | ★ 732.7K | 230.2K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | 3.00 |
| EPS | ★ 0.10 | N/A |
| Revenue | $95,420,129.00 | ★ $351,367,000.00 |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $135.00 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $9.90 | $2.78 |
| 52 Week High | $21.00 | $6.45 |
| Indicator | MAMA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 55.30 |
| Support Level | $13.06 | $5.13 |
| Resistance Level | $15.25 | $5.79 |
| Average True Range (ATR) | 0.86 | 0.21 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 18.92 | 53.33 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.